Abstract
Background. The Non-Hodgkin' s lymphoma (NHL) incidence increased significantly during last decades.
Numerous NHL subtypes with different biology vary in their distribution with respect to various geographical regions. We present the analysis of the Czech Lymphoma Study Group (CLSG) registry.
Methods: 3518 newly diagnosed NHL cases have been registered during the years 1999-2006. All cases were included into distribution analysis, only patients diagnosed until 2005 were included into survival analysis.
Results: The diffuse large B-cell lymphomas (DLBCL) represent the major subtype with 45%, followed by follicular lymphomas (FL) with 19%, marginal zone lymphomas with 7%, and mantle cell lymphomas with 6.5%. The DLBCL proportion is greater when compared with previously published data.
The proportion of FL varies significantly based on geographic region, with our figures within the range of published data. Overall survival (OS) probability at 3 years exceeded 80% in FL, primary mediastinal B-cell lymphomas (PMBCL), MALT type of MZL, and splenic MZL.
OS probability between 60-70% has been noticed in DLBCL, anaplastic large cell lymphomas (ALCL) and Burkitt_s lymphoma (BL). The worst outcome with steadily sloping curves and 3 year OS between 40-60% was observed in peripheral T-cell lymphomas not otherwise specified (PTL NOS), MCL, and T-lymphoblastic lymphomas.
More detailed analysis of DLBCL was performed and LDH, age, PS WHO, clinical stage, International prognostic index (IPI), rituximab therapy, high dose therapy with autologous stem cell transplantation, and year of diagnosis were found significant for OS as well as for progression free survival (PFS). Conclusion: The presented analysis describes for the first time the NHL lymphoma subtypes distribution as well as their outcome in Czech Republic.
The outcome improvement has been demonstrated by the introduction of new therapeutic approaches.